Included in the formulation
АТХ:C.10.A.X.13 Ewolokumab
Pharmacodynamics:Specific monoclonal antibody.Protein inhibits subtilisin / kexin convertase 9 (PCSK9), thereby preventing the destruction of low-density lipoprotein receptors in the liver.
Dose-dependent lowers the concentration of cholesterol and apolipoprotein B-100 in blood plasma by increasing the density of low-density lipoprotein receptors on hepatocytes. As a result, the capture of low density lipoproteins from the blood plasma increases.
Pharmacokinetics:After subcutaneous administration, the maximum concentration in the blood plasma is reached after 72 hours.
Therapeutic effect develops after 14 days after the beginning of the application. Metabolism in the liver.
The half-life period is 14 days. Elimination by the kidneys.
Indications:It is used to treat familial hypercholesterolemia as monotherapy, or in combination with statins.
IV.E70-E90.E78.0 Pure hypercholesterolemia
IV.E70-E90.E78.1 Pure hyperglyceridemia
IV.E70-E90.E78.2 Mixed hyperlipidemia
Contraindications:Hepatitis in the active phase, individual intolerance, children under 18 years.
Carefully:Chronic inflammatory processes in the liver, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - category is not defined. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously, 140 mg every 2 weeks, or 420 mg once a month.
The highest daily dose: 420 mg.
The highest single dose: 420 mg.
Side effects:Central and peripheral nervous system: asthenia, headache.
Musculoskeletal system: arthralgia, back pain, myalgia, tetany.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:In the treatment it is not recommended to drive vehicles and work with moving mechanisms.